Similar articles for PMID: 26593165

Year	Number of Results
1995	3
1996	1
2000	2
2001	2
2002	5
2003	4
2004	4
2005	7
2006	5
2007	3
2008	3
2009	6
2010	5
2011	7
2012	5
2013	9
2014	6
2015	3
2016	1
2017	1
2022	1
2024	0

1

Prostatic diseases under focus in a university hospital in Eastern Saudi Arabia. A 15-year experience.

Al Nemer AM, Aldamanhori RB. Al Nemer AM, et al. Saudi Med J. 2015 Nov;36(11):1319-23. doi: 10.15537/smj.2015.11.12654. Saudi Med J. 2015. PMID: 26593165 Free PMC article.

2

The clinicopathologic patterns of prostatic diseases and prostate cancer in Saudi patients.

Mosli HA, Abdel-Meguid TA, Al-Maghrabi JA, Kamal WK, Saadah HA, Farsi HM. Mosli HA, et al. Saudi Med J. 2009 Nov;30(11):1439-43. Saudi Med J. 2009. PMID: 19882057

3

Prostate inflammation. Association with benign prostatic hyperplasia and prostate cancer.

Abdel-Meguid TA, Mosli HA, Al-Maghrabi JA. Abdel-Meguid TA, et al. Saudi Med J. 2009 Dec;30(12):1563-7. Saudi Med J. 2009. PMID: 19936421

4

[Histological changes of the prostate and acute urinary retention in patients with benign prostatic hyperplasia].

Bao QB, He GH, Liu GY, Zhang CG, Yang C. Bao QB, et al. Zhonghua Nan Ke Xue. 2013 Sep;19(9):811-4. Zhonghua Nan Ke Xue. 2013. PMID: 24386860 Chinese.

5

Inflammation and chronic prostatic diseases: evidence for a link?

Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V. Sciarra A, et al. Eur Urol. 2007 Oct;52(4):964-72. doi: 10.1016/j.eururo.2007.06.038. Epub 2007 Jul 2. Eur Urol. 2007. PMID: 17618043 Review.

6

[Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].

Gao ZW, Liu G, Sheng BW. Gao ZW, et al. Ai Zheng. 2004 Jun;23(6):701-3. Ai Zheng. 2004. PMID: 15191675 Chinese.

7

Screening program for prostate cancer at a university hospital in eastern Saudi Arabia.

Taha SA, Kamal BA. Taha SA, et al. Saudi Med J. 2005 Jul;26(7):1104-6. Saudi Med J. 2005. PMID: 16047062 Clinical Trial.

8

[Influence of histological prostatitis on the clinical features of benign prostatic hyperplasia and prostate cancer].

Zhang F, Si-Mu-Jiang-Abula A, Zhang LD. Zhang F, et al. Zhonghua Nan Ke Xue. 2014 Apr;20(4):354-8. Zhonghua Nan Ke Xue. 2014. PMID: 24873164 Chinese.

9

Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.

Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP. Roehrborn CG, et al. BJU Int. 2011 Mar;107(6):946-54. doi: 10.1111/j.1464-410X.2011.10124.x. Epub 2011 Feb 18. BJU Int. 2011. PMID: 21332630 Clinical Trial.

10

[Differences in pathological features of histological inflammation between benign prostatic hyperplasia and prostate cancer].

Yang L, Zhao K, Zhang A, Liu LR, Liu ZH, Han P, Wei Q. Yang L, et al. Sichuan Da Xue Xue Bao Yi Xue Ban. 2013 Sep;44(5):760-3, 768. Sichuan Da Xue Xue Bao Yi Xue Ban. 2013. PMID: 24325107 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

76 results

Results by year